What is the 13F Pro Quality Score for IRD?

13F Pro ranks Opus Genetics, Inc. (IRD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IRD's current score at https://13fpro.ai/research/IRD (free sign-up required for the full ranking).

Where does 13F Pro source IRD data?

All Opus Genetics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Opus Genetics, Inc. files with the SEC under CIK 1228627. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IRD in?

Opus Genetics, Inc. (IRD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IRD research updated on 13F Pro?

IRD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Opus Genetics, Inc.(IRD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1228627 IRD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $39.9M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IRD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Opus Genetics, Inc. (IRD), a Healthcare sector company. IRD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $39.9m in revenue. Based on the latest XBRL financial filings (Q1 2026), Opus Genetics, Inc. reports quarterly revenue of $2.2M, net income of $-65.5M, free cash flow of $-12.7M. Top institutional holders of IRD by reported 13-F value include Caligan Partners, ADAGE CAPITAL PARTNERS GP, L.L.C., BIOS Capital Management,, based on the most recent SEC filings. IRD trades on the Nasdaq exchange and files with the SEC under CIK 1228627. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Opus Genetics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$2.2M

Net Income

Q1 2026

$-65.5M

Free Cash Flow

Q1 2026

$-12.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+29.1% YoY

$14.2MFY 2025

FY21 $589.0KFY23 $19.0MFY24 $11.0MFY25 $14.2M

Net Income

+13.8% YoY

$-49.6MFY 2025

FY21 $-56.7MFY23 $-10.0MFY24 $-57.5MFY25 $-49.6M

Operating Income

+37.8% YoY

$-38.6MFY 2025

FY21 $-22.7MFY23 $-10.6MFY24 $-62.1MFY25 $-38.6M

EPS (Diluted)

+62.8% YoY

$-0.80FY 2025

FY21 $-3.82FY23 $-0.46FY24 $-2.15FY25 $-0.80

Total Assets

+36.3% YoY

$50.2MFY 2025

FY21 $26.1MFY23 $53.9MFY24 $36.9MFY25 $50.2M

Total Debt

$1.1MFY 2025

FY21 $538.0KFY23 —FY24 $0.00FY25 $1.1M

Op. Cash Flow

-37.8% YoY

$-35.3MFY 2025

FY21 $-19.4MFY23 $-1.1MFY24 $-25.6MFY25 $-35.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2019	FY 2018
Revenue	$14.2M +29.1%	$11.0M -42.3%	$19.0M +3134.1%	$589.0K -80.4%	$3.0M	—
Net Income	$-49.6M +13.8%	$-57.5M -476.1%	$-10.0M +82.4%	$-56.7M -819.0%	$-6.2M +57.1%	$-14.4M
Operating Income	$-38.6M +37.8%	$-62.1M -487.7%	$-10.6M +53.5%	$-22.7M -441.5%	$-4.2M +79.6%	$-20.5M
EPS (Diluted)	$-0.80 +62.8%	$-2.15 -367.4%	$-0.46 +88.0%	$-3.82	—	—
Total Assets	$50.2M +36.3%	$36.9M -31.7%	$53.9M +106.9%	$26.1M +1361.7%	$1.8M -88.9%	$16.0M
Total Debt	$1.1M	$0.00	—	$538.0K	—	—
Operating Cash Flow	$-35.3M -37.8%	$-25.6M -2200.0%	$-1.1M +94.3%	$-19.4M -439.1%	$-3.6M +80.9%	$-18.8M

AI Insight: IRD Financial Trends

Opus Genetics burned through equity to negative territory in Q1 2026, with revenue collapsing 50% while operating losses widened.

• Revenue declined from $4M in Q4 2025 to $2M in Q1 2026, a 50% sequential drop. Full-year 2025 revenue of $14M showed no growth trajectory.

• Net losses accelerated sharply: Q1 2026 posted $66M loss versus $17M in Q4 2025, depleting equity to negative $46M.

• Operating cash flow remains deeply negative: $13M outflow in Q1 2026 with no signs of stabilization across eight quarters.

⚠ Company entered negative equity territory; solvency and runway to profitability now critical. No clear path to cash flow breakeven visible.

⚠ Operating income deteriorated to $14M loss in Q1 2026 after improving to $8M loss in Q3 2025. Trend reversal suggests operational stress.

AI Insight: IRD Ratio Trends

Opus Genetics remains unprofitable with sparse recent data; leverage briefly spiked in Q3 2025 before normalizing.

• Net profit margin deteriorated to -194.6% in Q3 2024 and -187.5% in Q1 2025, indicating sustained operating losses.

• Return on assets worsened from -69.3% in Q2 2024 to -76.8% in Q2 2025, signaling deteriorating asset efficiency.

• Debt-to-equity ratio spiked to 0.18 in Q3 2025, highest on record, before moderating to 0.07 in Q4 2025.

⚠ Consistent negative profitability across multiple quarters raises sustainability concerns without clear path to breakeven.

⚠ Data availability drops significantly from Q3 2025 onward; lack of recent metrics limits visibility on operational trajectory.

Get alerted when IRD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Opus Genetics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IRD

Caligan Partners LP
$27.6M6,075,028 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$27.4M6,029,775 sh
BIOS Capital Management, LP
$16.8M3,683,429 sh
BALYASNY ASSET MANAGEMENT L.P.
$12.4M2,718,029 sh
MILLENNIUM MANAGEMENT LLC
$12.0M2,630,432 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.1M2,449,987 sh
MARSHALL WACE, LLP
$10.5M2,313,380 sh
Boxer Capital Management, LLC
$10.2M2,250,000 sh
ADAR1 Capital Management, LLC
$8.4M1,849,004 sh
PERCEPTIVE ADVISORS LLC
$8.4M1,835,842 sh

Fund	Value	Shares
Caligan Partners LP	$27.6M	6,075,028
ADAGE CAPITAL PARTNERS GP, L.L.C.	$27.4M	6,029,775
BIOS Capital Management, LP	$16.8M	3,683,429
BALYASNY ASSET MANAGEMENT L.P.	$12.4M	2,718,029
MILLENNIUM MANAGEMENT LLC	$12.0M	2,630,432
VANGUARD CAPITAL MANAGEMENT LLC	$11.1M	2,449,987
MARSHALL WACE, LLP	$10.5M	2,313,380
Boxer Capital Management, LLC	$10.2M	2,250,000
ADAR1 Capital Management, LLC	$8.4M	1,849,004
PERCEPTIVE ADVISORS LLC	$8.4M	1,835,842

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IRD on your watchlist

Track score changes the day Opus Genetics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IRD a good stock to buy?

13F Pro's AI-powered analysis of Opus Genetics, Inc. (IRD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IRD are available on the IRD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IRD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IRD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Opus Genetics, Inc.'s investment landscape.